
WHAT IS CLAIMED IS:

1. A compound of the formula





wherein





X^1 and X^5 are each independently halo or –OH;


Y^1 and Y^2 are each independently –OH or –SH; and

A and B are each independently

 (**i**) and  (**ii**),


wherein the compound is one of the following:

or a stereoisomer or a pharmaceutically acceptable salt thereof.

2. The compound according to claim 1 which is



or a stereoisomer or a pharmaceutically acceptable salt thereof.

3. A pharmaceutical composition comprising a compound according to claim 1 or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable carriers, diluents or excipients.

4. A combination pharmaceutical product comprising a compound according to claim 1 or a pharmaceutically acceptable salt thereof together with one or more other therapeutically active agents.

5. A compound according to claim 1 or a pharmaceutically acceptable salt thereof for use in therapy.

6. A compound according to claim 1 or a pharmaceutically acceptable salt thereof for use in the treatment of diseases or conditions that may be alleviated by the induction of an immune response via the STING pathway.

7. A compound according to claim 1 or a pharmaceutically acceptable salt thereof for use in the treatment of diseases and conditions in which the modulation of STING is indicated in a subject in need thereof, wherein a therapeutically effective amount of the compound or the pharmaceutically acceptable salt thereof is to be administered.

8. A compound according to claim 1 or a pharmaceutically acceptable salt thereof for use in the treatment of cancer, wherein a therapeutically effective amount of one or more of the compound or the pharmaceutically acceptable salt thereof is to be administered.

9. The compound or the pharmaceutically acceptable salt thereof for use according to claim 8 wherein the cancer is melanoma, carcinoma, lymphoma, blastoma, sarcoma, and leukemia or lymphoid malignancies, breast cancer, colon cancer, rectal cancer, colorectal cancer, kidney or renal cancer, clear cell cancer lung cancer including small-cell lung cancer, non- small cell lung cancer, adenocarcinoma of the lung and squamous carcinoma of the lung, squamous cell cancer, epithelial squamous cell cancer, cervical cancer, ovarian cancer, prostate cancer, prostatic neoplasms, liver cancer, bladder cancer, cancer of the peritoneum, hepatocellular cancer, gastric or stomach cancer including gastrointestinal cancer, gastrointestinal stromal tumor, pancreatic cancer, head and neck cancer, glioblastoma, retinoblastoma, astrocytoma, thecomas, arrhenoblastomas, hepatoma, hematologic malignancies including non-Hodgkins lymphoma (NHL), multiple myeloma, myelodysplasia disorders, myeloproliferative disorders, chronic myelogenous leukemia, and acute hematologic malignancies, endometrial or uterine carcinoma, endometriosis, endometrial stromal sarcoma, fibrosarcomas, choriocarcinoma, salivary gland carcinoma, vulval cancer, thyroid cancer, esophageal carcinomas, hepatic carcinoma, anal carcinoma, penile carcinoma, nasopharyngeal carcinoma, laryngeal carcinomas, Kaposi's sarcoma, mast cell sarcoma, ovarian sarcoma, uterine sarcoma, melanoma, malignant mesothelioma, skin carcinomas, Schwannoma, oligodendroglioma, neuroblastomas, neuroectodermal tumor, rhabdomyosarcoma, osteogenic sarcoma, leiomyosarcomas, Ewing Sarcoma, peripheral primitive neuroectodermal tumor, urinary tract carcinomas, thyroid carcinomas, Wilm's tumor, as well as abnormal vascular proliferation associated with phakomatoses, edema (such as that associated with brain tumors) or Meigs' syndrome.

10. The compound or the pharmaceutically acceptable salt thereof for use according to claim 9 wherein the cancer is small cell lung cancer, non-small cell lung cancer, colorectal cancer, melanoma, renal cancer, carcinoma, head and neck canceror bladder cancer.

11. A compound according to claim 1, or a pharmaceutically acceptable salt thereof for use in the treatment of cancer in a subject in need thereof, wherein an effective amount of the compound or the pharmaceutically acceptable salt thereof is to be administered in combination with a therapeutically effective amount of one or more immuno-oncology agents.

12. The compound or the pharmaceutically acceptable salt thereof for use according to claim 11, wherein the immuno-oncology agent is ipilimumab.


13. The compound or the pharmaceutically acceptable salt thereof for use according to claim 11, wherein the immuno-oncology agent is a PD-L1 antagonist.

14. A compound according to claim 1, or a pharmaceutically acceptable salt thereof for use in the treatment of cancer in a subject, wherein a therapeutically effective amount of the compound or the pharmaceutically acceptable salt thereof is to be administered in combination with a therapeutically effective amount of an anti-cancer agent which is an antibody or an antigen-binding portion thereof that binds specifically to a Programmed Death-1 (PD-1) receptor and inhibits PD-1 activity.

15. The compound or the pharmaceutically acceptable salt thereof for use according to claim 14, wherein the anti-PD-1 antibody is nivolumab or pembrolizumab.


16. The compound or the pharmaceutically acceptable salt thereof for use according to claim 18, wherein the anti-PD-1 antibody is nivolumab.

17. A compound which is



.

18. A compound which is



.